Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 265 to 270 of 270 entries
Sorted by: Best Match Show Resources per page
Maternal smoking trajectory during pregnancy predicts offspring's smoking and substance use - The Northern Finland birth cohort 1966 study.

Preventive medicine reports

Rissanen I, Paananen M, Harju T, Miettunen J, Oura P.
PMID: 34194967
Prev Med Rep. 2021 Jun 23;23:101467. doi: 10.1016/j.pmedr.2021.101467. eCollection 2021 Sep.

The aim was to characterize the association of maternal smoking trajectory during pregnancy with offspring's smoking, alcohol and substance use behavior. We used the prospective Northern Finland Birth Cohort 1966 study including 11,653 mothers and their offspring followed up...

Cite
Rissanen I, Paananen M, Harju T, et al. Maternal smoking trajectory during pregnancy predicts offspring's smoking and substance use - The Northern Finland birth cohort 1966 study. Prev Med Rep. 2021;23:101467doi: 10.1016/j.pmedr.2021.101467.
Rissanen, I., Paananen, M., Harju, T., Miettunen, J., & Oura, P. (2021). Maternal smoking trajectory during pregnancy predicts offspring's smoking and substance use - The Northern Finland birth cohort 1966 study. Preventive medicine reports, 23101467. https://doi.org/10.1016/j.pmedr.2021.101467
Rissanen, Ina, et al. "Maternal smoking trajectory during pregnancy predicts offspring's smoking and substance use - The Northern Finland birth cohort 1966 study." Preventive medicine reports vol. 23 (2021): 101467. doi: https://doi.org/10.1016/j.pmedr.2021.101467
Rissanen I, Paananen M, Harju T, Miettunen J, Oura P. Maternal smoking trajectory during pregnancy predicts offspring's smoking and substance use - The Northern Finland birth cohort 1966 study. Prev Med Rep. 2021 Jun 23;23:101467. doi: 10.1016/j.pmedr.2021.101467. eCollection 2021 Sep. PMID: 34194967; PMCID: PMC8237583.
Copy Download .nbib Format: NLM
Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling.

ACS applied bio materials

Goodall CP, Schwarz B, Selivanovitch E, Avera J, Wang J, Miettinen H, Douglas T.
PMID: 35005938
ACS Appl Bio Mater. 2021 Dec 20;4(12):8205-8214. doi: 10.1021/acsabm.1c00718. Epub 2021 Nov 10.

Ligands of the tumor necrosis factor superfamily (TNFSF) are appealing targets for immunotherapy research due to their integral involvement in stimulation or restriction of immune responses. TNFSF-targeted therapies are currently being developed to combat immunologically based diseases and cancer....

Cite
Goodall CP, Schwarz B, Selivanovitch E, et al. Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling. ACS Appl Bio Mater. 2021;4(12):8205-8214doi: 10.1021/acsabm.1c00718.
Goodall, C. P., Schwarz, B., Selivanovitch, E., Avera, J., Wang, J., Miettinen, H., & Douglas, T. (2021). Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling. ACS applied bio materials, 4(12), 8205-8214. https://doi.org/10.1021/acsabm.1c00718
Goodall, Cheri Peyton, et al. "Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling." ACS applied bio materials vol. 4,12 (2021): 8205-8214. doi: https://doi.org/10.1021/acsabm.1c00718
Goodall CP, Schwarz B, Selivanovitch E, Avera J, Wang J, Miettinen H, Douglas T. Controlled Modular Multivalent Presentation of the CD40 Ligand on P22 Virus-like Particles Leads to Tunable Amplification of CD40 Signaling. ACS Appl Bio Mater. 2021 Dec 20;4(12):8205-8214. doi: 10.1021/acsabm.1c00718. Epub 2021 Nov 10. PMID: 35005938.
Copy Download .nbib Format: NLM
Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study.

Rheumatology and therapy

Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, Marshall DA.
PMID: 34275124
Rheumatol Ther. 2021 Sep;8(3):1303-1322. doi: 10.1007/s40744-021-00331-x. Epub 2021 Jul 18.

INTRODUCTION: Juvenile idiopathic arthritis (JIA) is a chronic rheumatic disease, whose multifaceted care path can lead to significant expenditure for the healthcare system. We aim to assess the real-world healthcare resource use (HCRU) and associated cost for children with...

Cite
Grazziotin LR, Currie G, Twilt M, et al. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatol Ther. 2021;8(3):1303-1322doi: 10.1007/s40744-021-00331-x.
Grazziotin, L. R., Currie, G., Twilt, M., Ijzerman, M. J., Kip, M. M. A., Koffijberg, H., Benseler, S. M., Swart, J. F., Vastert, S. J., Wulffraat, N. M., Yeung, R. S. M., Johnson, N., Luca, N. J., Miettunen, P. M., Schmeling, H., Marshall, D. A. (2021). Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatology and therapy, 8(3), 1303-1322. https://doi.org/10.1007/s40744-021-00331-x
Grazziotin, Luiza R, et al. "Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study." Rheumatology and therapy vol. 8,3 (2021): 1303-1322. doi: https://doi.org/10.1007/s40744-021-00331-x
Grazziotin LR, Currie G, Twilt M, Ijzerman MJ, Kip MMA, Koffijberg H, Benseler SM, Swart JF, Vastert SJ, Wulffraat NM, Yeung RSM, Johnson N, Luca NJ, Miettunen PM, Schmeling H, Marshall DA. Evaluation of Real-World Healthcare Resource Utilization and Associated Costs in Children with Juvenile Idiopathic Arthritis: A Canadian Retrospective Cohort Study. Rheumatol Ther. 2021 Sep;8(3):1303-1322. doi: 10.1007/s40744-021-00331-x. Epub 2021 Jul 18. PMID: 34275124; PMCID: PMC8380593.
Copy Download .nbib Format: NLM
Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?.

Frontiers in psychiatry

Jääskeläinen E, Miettunen J, Ahmed AO.
PMID: 33329164
Front Psychiatry. 2020 Nov 27;11:618417. doi: 10.3389/fpsyt.2020.618417. eCollection 2020.

No abstract available.

Cite
Jääskeläinen E, Miettunen J, Ahmed AO. Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?. Front Psychiatry. 2020;11:618417doi: 10.3389/fpsyt.2020.618417.
Jääskeläinen, E., Miettunen, J., & Ahmed, A. O. (2020). Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?. Frontiers in psychiatry, 11618417. https://doi.org/10.3389/fpsyt.2020.618417
Jääskeläinen, Erika, et al. "Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?." Frontiers in psychiatry vol. 11 (2020): 618417. doi: https://doi.org/10.3389/fpsyt.2020.618417
Jääskeläinen E, Miettunen J, Ahmed AO. Editorial: Have We Got Better in Making Our Schizophrenia Patients Better?. Front Psychiatry. 2020 Nov 27;11:618417. doi: 10.3389/fpsyt.2020.618417. eCollection 2020. PMID: 33329164; PMCID: PMC7728736.
Copy Download .nbib Format: NLM
Cohort Profile: 46 years of follow-up of the Northern Finland Birth Cohort 1966 (NFBC1966).

International journal of epidemiology

Nordström T, Miettunen J, Auvinen J, Ala-Mursula L, Keinänen-Kiukaanniemi S, Veijola J, Järvelin MR, Sebert S, Männikkö M.
PMID: 34458907
Int J Epidemiol. 2021 Aug 29; doi: 10.1093/ije/dyab109. Epub 2021 Aug 29.

No abstract available.

Cite
Nordström T, Miettunen J, Auvinen J, et al. Cohort Profile: 46 years of follow-up of the Northern Finland Birth Cohort 1966 (NFBC1966). Int J Epidemiol. 2021;doi: 10.1093/ije/dyab109.
Nordström, T., Miettunen, J., Auvinen, J., Ala-Mursula, L., Keinänen-Kiukaanniemi, S., Veijola, J., Järvelin, M. R., Sebert, S., & Männikkö, M. (2021). Cohort Profile: 46 years of follow-up of the Northern Finland Birth Cohort 1966 (NFBC1966). International journal of epidemiology, . https://doi.org/10.1093/ije/dyab109
Nordström, Tanja, et al. "Cohort Profile: 46 years of follow-up of the Northern Finland Birth Cohort 1966 (NFBC1966)." International journal of epidemiology vol. (2021). doi: https://doi.org/10.1093/ije/dyab109
Nordström T, Miettunen J, Auvinen J, Ala-Mursula L, Keinänen-Kiukaanniemi S, Veijola J, Järvelin MR, Sebert S, Männikkö M. Cohort Profile: 46 years of follow-up of the Northern Finland Birth Cohort 1966 (NFBC1966). Int J Epidemiol. 2021 Aug 29; doi: 10.1093/ije/dyab109. Epub 2021 Aug 29. PMID: 34458907; PMCID: PMC8743124.
Copy Download .nbib Format: NLM
A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies.

Microbiology spectrum

Solastie A, Virta C, Haveri A, Ekström N, Kantele A, Miettinen S, Lempainen J, Jalkanen P, Kakkola L, Dub T, Julkunen I, Melin M.
PMID: 34787485
Microbiol Spectr. 2021 Nov 17;e0113121. doi: 10.1128/Spectrum.01131-21. Epub 2021 Nov 17.

Validation and standardization of accurate serological assays are crucial for the surveillance of the coronavirus disease 2019 (COVID-19) pandemic and population immunity. We describe the analytical and clinical performance of an in-house fluorescent multiplex immunoassay (FMIA) for simultaneous quantification...

Cite
Solastie A, Virta C, Haveri A, et al. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiol Spectr. 2021;e0113121doi: 10.1128/Spectrum.01131-21.
Solastie, A., Virta, C., Haveri, A., Ekström, N., Kantele, A., Miettinen, S., Lempainen, J., Jalkanen, P., Kakkola, L., Dub, T., Julkunen, I., & Melin, M. (2021). A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiology spectrum, e0113121. https://doi.org/10.1128/Spectrum.01131-21
Solastie, Anna, et al. "A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies." Microbiology spectrum vol. (2021): e0113121. doi: https://doi.org/10.1128/Spectrum.01131-21
Solastie A, Virta C, Haveri A, Ekström N, Kantele A, Miettinen S, Lempainen J, Jalkanen P, Kakkola L, Dub T, Julkunen I, Melin M. A Highly Sensitive and Specific SARS-CoV-2 Spike- and Nucleoprotein-Based Fluorescent Multiplex Immunoassay (FMIA) to Measure IgG, IgA, and IgM Class Antibodies. Microbiol Spectr. 2021 Nov 17;e0113121. doi: 10.1128/Spectrum.01131-21. Epub 2021 Nov 17. PMID: 34787485; PMCID: PMC8597651.
Copy Download .nbib Format: NLM
Showing 265 to 270 of 270 entries